Biocon Limited — Others, 07-08-2025: Monitoring Agency Report

Biocon has received and reviewed the Monitoring Agency Report for its Qualified Institutions Placement (QIP) proceeds utilization for the quarter ended June 30, 2025. The report confirms there was no deviation from the stated QIP objectives. Out of the 4,500 Cr raised, the company has utilized approximately 1,698.57 Cr, primarily for purchasing outstanding debentures of its Biocon Biologics subsidiary. The remaining 2,801.43 Cr is unutilized and deployed in short-term money market instruments. This update reassures stakeholders regarding the transparent use of capital raised.